Formosa Laboratories, Inc. (4746.TW)
TWD 71.9
(-0.96%)
TWD 71.9
(-0.96%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 4.06 Billion TWD | 6.93% |
| 2022 | 3.8 Billion TWD | 11.07% |
| 2021 | 3.42 Billion TWD | 8.17% |
| 2020 | 3.16 Billion TWD | -13.35% |
| 2019 | 3.65 Billion TWD | 23.23% |
| 2018 | 2.96 Billion TWD | 154.97% |
| 2017 | 1.16 Billion TWD | 8.51% |
| 2016 | 1.07 Billion TWD | -44.31% |
| 2015 | 1.92 Billion TWD | 4.74% |
| 2014 | 1.83 Billion TWD | 11.11% |
| 2013 | 1.65 Billion TWD | -12.16% |
| 2012 | 1.88 Billion TWD | 145.71% |
| 2011 | 765.5 Million TWD | 23.69% |
| 2010 | 618.89 Million TWD | 0.0% |
| 2009 | - TWD | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q2 | 3.73 Billion TWD | -4.99% |
| 2024 Q1 | 3.92 Billion TWD | -3.35% |
| 2023 FY | 4.06 Billion TWD | 6.93% |
| 2023 Q4 | 4.06 Billion TWD | 3.37% |
| 2023 Q3 | 3.93 Billion TWD | -0.37% |
| 2023 Q2 | 3.94 Billion TWD | 6.29% |
| 2023 Q1 | 3.71 Billion TWD | -2.31% |
| 2022 Q1 | 3.35 Billion TWD | -1.97% |
| 2022 Q4 | 3.8 Billion TWD | 4.81% |
| 2022 Q2 | 3.25 Billion TWD | -2.96% |
| 2022 FY | 3.8 Billion TWD | 11.07% |
| 2022 Q3 | 3.62 Billion TWD | 11.39% |
| 2021 Q1 | 3.35 Billion TWD | 5.94% |
| 2021 Q2 | 3.28 Billion TWD | -2.03% |
| 2021 FY | 3.42 Billion TWD | 8.17% |
| 2021 Q3 | 3.22 Billion TWD | -1.9% |
| 2021 Q4 | 3.42 Billion TWD | 6.23% |
| 2020 FY | 3.16 Billion TWD | -13.35% |
| 2020 Q1 | 3.55 Billion TWD | -2.65% |
| 2020 Q3 | 2.76 Billion TWD | -25.34% |
| 2020 Q4 | 3.16 Billion TWD | 14.21% |
| 2020 Q2 | 3.71 Billion TWD | 4.39% |
| 2019 FY | 3.65 Billion TWD | 23.23% |
| 2019 Q4 | 3.65 Billion TWD | 3.63% |
| 2019 Q3 | 3.52 Billion TWD | 1.27% |
| 2019 Q2 | 3.47 Billion TWD | 3.93% |
| 2019 Q1 | 3.34 Billion TWD | 12.98% |
| 2018 Q3 | 2.32 Billion TWD | 12.63% |
| 2018 Q2 | 2.06 Billion TWD | 24.36% |
| 2018 Q1 | 1.65 Billion TWD | 42.68% |
| 2018 FY | 2.96 Billion TWD | 154.97% |
| 2018 Q4 | 2.96 Billion TWD | 27.58% |
| 2017 Q1 | 1.25 Billion TWD | 17.56% |
| 2017 Q4 | 1.16 Billion TWD | -14.29% |
| 2017 Q3 | 1.35 Billion TWD | -4.72% |
| 2017 Q2 | 1.42 Billion TWD | 13.02% |
| 2017 FY | 1.16 Billion TWD | 8.51% |
| 2016 Q1 | 2.16 Billion TWD | 12.42% |
| 2016 Q4 | 1.07 Billion TWD | -15.67% |
| 2016 Q2 | 2.05 Billion TWD | -4.99% |
| 2016 FY | 1.07 Billion TWD | -44.31% |
| 2016 Q3 | 1.26 Billion TWD | -38.17% |
| 2015 Q3 | 2.03 Billion TWD | 4.11% |
| 2015 FY | 1.92 Billion TWD | 4.74% |
| 2015 Q4 | 1.92 Billion TWD | -5.44% |
| 2015 Q2 | 1.95 Billion TWD | 0.04% |
| 2015 Q1 | 1.95 Billion TWD | 6.36% |
| 2014 Q2 | 1.61 Billion TWD | 3.72% |
| 2014 Q1 | 1.55 Billion TWD | -5.7% |
| 2014 Q4 | 1.83 Billion TWD | 11.84% |
| 2014 FY | 1.83 Billion TWD | 11.11% |
| 2014 Q3 | 1.64 Billion TWD | 1.57% |
| 2013 Q1 | 2.04 Billion TWD | 8.79% |
| 2013 Q2 | 2.38 Billion TWD | 16.53% |
| 2013 Q3 | 2.03 Billion TWD | -14.68% |
| 2013 Q4 | 1.65 Billion TWD | -18.79% |
| 2013 FY | 1.65 Billion TWD | -12.16% |
| 2012 Q4 | 1.88 Billion TWD | 28.12% |
| 2012 Q1 | 888.64 Million TWD | 16.09% |
| 2012 Q2 | 1.08 Billion TWD | 21.62% |
| 2012 FY | 1.88 Billion TWD | 145.71% |
| 2012 Q3 | 1.46 Billion TWD | 35.83% |
| 2011 Q3 | 704.63 Million TWD | 176.33% |
| 2011 Q4 | 765.5 Million TWD | 8.64% |
| 2011 Q1 | 213.2 Million TWD | -65.55% |
| 2011 Q2 | 254.99 Million TWD | 19.61% |
| 2011 FY | 765.5 Million TWD | 23.69% |
| 2010 FY | 618.89 Million TWD | 0.0% |
| 2010 Q4 | 618.89 Million TWD | 0.0% |
| 2009 FY | - TWD | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Grape King Bio Ltd | 192.92 Million TWD | -2006.783% |
| Standard Chem & Pharm CO., LTD. | 1.08 Billion TWD | -275.638% |
| Maywufa Company Ltd. | 442.66 Million TWD | -818.165% |
| ScinoPharm Taiwan, Ltd. | 621.1 Million TWD | -554.385% |
| Lotus Pharmaceutical Co., Ltd. | 11.58 Billion TWD | 64.916% |
| LIWANLI Innovation Co., Ltd. | 2.63 Million TWD | -154088.392% |
| YungShin Global Holding Corporation | 1.23 Billion TWD | -227.927% |
| PhytoHealth Corporation | 28.11 Million TWD | -14356.361% |
| SCI Pharmtech, Inc. | 1.04 Billion TWD | -289.881% |
| PharmaEssentia Corporation | 1.2 Billion TWD | -238.638% |
| Bora Pharmaceuticals Co., LTD. | 5 Billion TWD | 18.872% |